|Title of Invention||
METHOD FOR DETERMINING A WARFARIN DOSE
|Abstract||We discovered that a polymorphism in the promoter of the VKORCI gene is associated with warfarin sensitivity. This polymorphism can explain both the inter individual and inter-ethnic differences in warfarin dose requirements. Furthermore, the polymorphism is also associated with promoter activity. Thus, the promoter sequence or activity of the VKORCI gene of a subject can be used to predict how much warfarin should be prescribed for the subject. Relevant methods and compositions are provided.|
|Full Text|| FORM 2
THE PATENT ACT 1970
(39 of 1970)
The Patents Rules, 2003 COMPLETE SPECIFICATION (See section 10 and rule 13)
1. GENETIC VARIANTS PREDICTING WARFARIN SENSITIVITY.
(A) ACADEMIA SINICA
(C) 128 Sec. 2, Academia Sinica Road, Nan-Kang, Taipei,
The following specification particularly describes the invention and the manner in which it is to be performed.
13 JUL 2007
This invention relates to methods of dosing drugs, particularly warfarin.
1. Hirsh, J. (1992) Antithrombotic therapy in deep vein thrombosis and pulmonary embolism. Am. Heart J., 123, 1115-1122.
2. Laupacis, A., Albers, G., Dalen, J., Dunn, M., Feinberg, W. and Jacobson, A. (1995) Antithrombotic therapy in atrial fibrillation. Chest, 108,352S-359S.
3. Stein, P.D., Alpert, J.S., Copeland, J., Dalen, J.E., Goldman, S. and Turpie, A.G. (1995) Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest, 108, "371S-379S.
4. Hirsh, J., Dalen, J., Anderson, D.R., Poller, L., Bussey, H., Ansell, J. and Deykin, D. (2001) Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest, 119, 8S-21S.
5. Loebstein, R., Yonath, H., Peleg, D., Almog, S., Rotenberg, M., Lubetsky, A., Roitelman, J., Harats, D., Halkin, H. and Ezra, D. (2001) Interindividual variability in sensitivity to warfarin—Nature or nurture? Clin. Pharmacol. Ther., 70,159-164.
6. Takahashi, H., Wilkinson, G.R., Caraco, Y., Muszkat, M., Kim, R.B., Kashima, T., Kimura, S. and Echizen, H. (2003) Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin. Pharmacol. Ther., 73, 253^263.
1. Zhao, F, Loke, C, Rankin, S.C., Guo, J.Y., Lee, H.S, Wu, T.S, Tan, T, Liu, T.C., Lu,W, Lim, Y.T. et al. (2004) Novel CYP2C9 genetic variants in
Asian subjects and their influence on maintenance warfarin dose. Clin. Pharmacol. Ther., 76,210-219.
8. Yu, H.C., Chan, T.Y., Critchley, J.A. and Woo, K.S. (1996) Factors determining the maintenance dose of warfarin in Chinese patients. QJM, 89, 127-135.
9. Xie, H.G., Kim, R.B., Wood, A.J, and Stein, CM. (2001) Molecular basis of ethnic differences in drug disposition and response. Annu. Rev. Pharmacol. Toxicol, 41,815-850.
10. Bogousslavsky, J. and Regli, F. (1985) Anticoagulant-induced intracerebral bleeding in brain ischemia. Evaluation in 200 patients with TIAs, emboli from the heart, and progressing stroke. Acta. Neurol. Scand., 71,464-471.
11. Landefeld, C.S. and Beyth, R.J. (1993) Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am. J. Med., 95, 315-328.
12. Gullov, A.L., Koefoed, B.G. and Petersen, P. (1994) Bleeding Complications to Long-Term Oral Anticoagulant Therapy. J. Thromb. Thrombolysis, 1,17-25.
13. Kaminsky, L.S., Dunbar, D.A., Wang, P.P., Beaune, P., Larrey, D., Guengerich, F.P., Schnellmann, R.G. and Sipes, I.G. (1984) Human hepatic cytochrome P-450 composition as probed by in vitro microsomal metabolism of warfarin. DrugMetab. Dispos., 12,470-477.
14. Rettie, A.E., Korzekwa, K.R., Kunze, K.L., Lawrence, R.F., Eddy, A.C., Aoyama, T., Gelboin, H.V., Gonzalez, F.J. and Trager, W.F. (1992) Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem. Res. Toxicol., 5, 54-59.
15. Kaminsky, L.S., de Morais, S.M., Faletto, M.B., Dunbar, D.A. and Goldstein, J.A. (1993) Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. Mol. Pharmacol, 43, 234-239.
16. Xie, H.G., Prasad, H.C., Kim, R.B. and Stein, CM. (2002) CYP2C9 allelic variants: ethnic distribution and functional significance. Adv. Drug. Deliv. Rev., 54,1257-1270.
17. Kirchheiner, J. and Brockmoller, J. (2005) Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther., 77,1-16.
18. Furuya, H., Fernandez-Salguero, P., Gregory, W., Taber, H., Steward, A., Gonzalez, F.J. and Idle, J.R. (1995) Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics, 5, 389-392,
19. Aithal, G.P., Day, C.P., Kesteven, P.J. and Daly, A.K. (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet, 353, 717-719.
20. Higashi, M.K., Veenstra, D.L., Kondo, L.M., Wittkowsky, A.K., Srinouanprachanh, S.L., Farin, F.M. and Rettie, A.E. (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA, 287,1690-1698.
21. Nasu, K., Kubota, T. and Ishizaki, T. (1997) Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics, 7,405-409.
22. Bell, R.G. and Matschiner, J.T. (1972) Warfarin and the inhibition of vitamin K activity by an oxide metabolite. Nature, 237, 32-33.
23. Wallin, R. and Martin, L.F. (1985) Vitamin Independent carboxylation and vitamin K metabolism in liver. Effects of warfarin. J, Clin. Invest, 76,1879-1884.
24. Li, T., Chang, C.Y., Jin, D.Y., Lin, P.J., Khvorova, A. and Stafford, D.W. (2004) Identification of the gene for vitamin K. epoxide reductase. Nature, 427,541-544.
25. Rost, S., Fregin, A., Ivaskevicius, V., Conzelmann, E., Hortnagel, K., Pelz, H.J., Lappegard, K... Seifried, E., Scharrer, I., Tuddenham, E.G. et al, (2004) Mutations in VK.ORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature, 427,537-541.
26. Harrington, D.J., Underwood, S., Morse, C, Shearer, M.J., Tuddenham, E.G.
"'and Mumford, A.D. (2005) Pharmacodynamic resistance to warfarin
associated with a Val66Met substitution in vitamin K. epoxide reductase complex subunit 1. Thromb. Haemost., 93, 23-26.
27. DAndrea, G., D'Ambrosio, R.L., Di Pema, P., Chetta, M., Santacroce, R.,
Brancaccio, V., Grandone, E. and Margaglione, M. (2005) A polymorphism in
the VKORC1 gene is associated with an interindividua! variability in the dose-
anticoagulant effect of warfarin. Blood, 105,645-649.
28. Massari, M.E. and Murre, C. (2000) Helix-loop-helix proteins: regulators of transcription in eucaryotic organisms. Mol. Cell Biol., 20,429-440.
29. Terai, S., Aoki, H., Ashida, K. and Thorgeirsson, S.S. (2000) Human homologue of maid: A dominant inhibitory helix-loop-helix protein associated with liver-specific gene expression. Hepatology, 32,357-366.
30. Bodin, L., Verstuyft, C, Tregouet, D.A., Robert, A., Dubert, L., Funck-Brentano, C, Jaillon, P., Beaune, P., Laurent-Puig, P., Becquemont, L. etal. (2005) Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood, 106(1):135-140.
31. Jones, K.A., Kadonaga, J.T., Rosenfeld, P.J., Kelly, T.J. and Tjian, R. (1987) A cellular DNA-binding protein that activates eukaryotic transcription and DNA replication. Cell, 48, 79-89.
32. Rieder, M. J., A. P. Reiner, et al. (2005). Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. NEnglJMed, 352(22): 2285-93.
33. Geisen, C, M. Watzka, et al. (2005). VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost, 94(4): 773-9.
34. Veenstra, D. L., J. H. You, et al. (2005). Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet Genomics, 15(10): 687-91.
35. Sconce, E. A., T. I. Khan, et al. (2005). The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood, 106(7): 2329-33.
All of the publications, patents and patent applications cited above or elsewhere in this application are herein incorporated by reference in their entirety to the same extent as if the disclosure of each individual publication, patent application or patent was specifically and individually indicated to be incorporated by reference in its entirety.
Warfarin is a widely prescribed anticoagulant for the prevention of thromboembolic diseases for subjects with deep vein thrombosis, atrial fibrillation, or
mechanical heart valve replacement (1-4). However, warfarin treatment is problematic because the dose requirement for warfarin is highly variable, both inter-individually and inter-ethnically (5-7). Asian populations, including the Chinese, generally require a much lower maintenance dose than Caucasians and Hispanics (6-9). B|eeding is by far the most serious complication of warfarin treatment (10-12). Much effort has been devoted to monitor the safety of this oral anticoagulant. Currently, the dose has to be closely monitored by serial determinations of blood prothrombin time using standardized international normalized ratio (INR).
Cytochrome P450, subfamily I1C, polypeptide 9 (CYP2C9) is the principal drug metabolizing enzyme that catalyzes the hydroxylation of warfarin (13-15). CYP2C9*2 and CYP2C9*3 are the polymorphisms most frequently found in the Caucasian population. Taking CYP2C9*1 as wild type, the haplotype frequencies for CYP2C9*l/*2 and CYP2C9*l/*3 are - 20% and -12% respectively (16, 17). The CYP2C9*2 and CYP2C9*3 variants have been shown to decrease the enzymatic activity of CYP2C9, which leads to warfarin sensitivity and, in serious cases, bleeding complications (18-20). However, both CYP2C9*2 and CYP2C9*3 are either completely absent or rare in the Asian populations (9, 21). Genetic variants discovered in CYP2C9 thus far can only partially explain some of the inter-individual differences in warfarin dosage, but they cannot explain the inter-ethnic differences (6, 7,16).
Gamma-carboxylation of vitamin K-dependent clotting factors (factor II, VII, IX, and X) is essential for blood clotting. The gamma-carboxylase uses the reduced form of vitamin K and oxygen to add a carbon dioxide molecule to the side chain of glutamic acid in the clotting factors. During carboxylation, the reduced vitamin K. is oxidized to vitamin K 2,3-epoxide, from which the reduced vitamin K is regenerated by vitamin K epoxide reductase for another cycle of catalysis. "Warfarin blocks clotting factor synthesis by inhibiting vitamin K. epoxide reductase (22, 23). Recently, the gene coding for vitamin K epoxide reductase complex, subunit 1 (VKORC1) has been cloned (24, 25) and mutations in VKORC1 gene were found in warfarin resistant patients (25, 26). An intronic polymorphism was also discovered to be associated with certain warfarin inter-individual variability in Italian patients (27).
These studies cannot explain all the warfarin dosage variability, particularly the inter-ethnic variation. Furthermore, a large part of the world's population, the Asians, is unaccounted for. Therefore, it is desirable to find a method for predicting the proper warfarin dose range that can be more widely applied.
In this study, we discovered that a polymorphism in the promoter of the VKORCI gene is associated with warfarin sensitivity. This polymorphism can explain both the inter-individual and inter-ethnic differences in warfarin dose requirements. Furthermore, the polymorphism is also associated with promoter activity. The VKORCI promoter having a G at the -1639 position (numbered with respect to the first nucleotide of the initiation codon) is 44% more active than the promoter having an A at the same position. Patients with the -1639A polymorphism are more sensitive to warfarin. Homozygous AA patients at the -1639 position had the lowest dose requirements, heterozygous AG had intermediate dose requirements and the homozygous GG patients had the highest dosage. Thus, the promoter sequence or activity of the VKORCI gene of a subject can be used to predict how much warfarin should be prescribed for the subject. This method significantly improves the accuracy of warfarin dosing. Currently, patients are given an initial dose, their INR monitored periodically and warfarin dosage adjusted accordingly, until a maintenance dose that is safe for the patient can be achieved. With the present invention, the predicted dose will be much closer to the maintenance dose, thus warfarin dosing will be quicker, safer, and more economical.
Accordingly, one aspect of the present invention provides a method of determining the dose range of warfarin for a subject, comprising investigating the sequence of the promoter of the VKORCI gene of the subject. Another aspect of the present invention provides a method of assessing the risk of complication after a patient takes warfarin, comprising investigating the sequence of the promoter of the VKORCI gene of the subject. The more sensitive the subject is to warfarin, the higher is the risk to develop complications, such as bleeding.
In particular, the sequence at the -1639 position of" the VKORCI gene is investigated. If the nucleotide at this position is an A, the subject is more sensitive to warfarin. Thus, a subject having homozygous AA at the -1639 position of the VKORCI gene is more sensitive than a heterozygote having an A and another nucleotide (G, C or T) at this position. In turn, the same heterozygote is more sensitive to warfarin than a subject having no A at this position.
The sequence can be investigated by assaying for an equivalent genetic marker of the -1639Aor -1639G/OT allele, wherein the presence of the equivalent genetic marker is indicative of the presence of the corresponding allele. For example, the equivalent genetic marker may be an SNP selected from the group consisting of rs9934438, rs8050894, rs2359612 and rs7294 of the VKORCI gene, each of which is indicative of warfarin sensitivity.
In some embodiments of the present invention, the sequence is investigated by using an oligonucleotide that specifically hybridizes with (he promoter of the VKORCI gene. Preferably, the oligonucleotide specifically hybridizes with at least 6, 8,10,12,14, 16, 18, 20,22 or24 nucleotides spanning the-1639 position of the VKORCI gene. The sequence may be investigated by using DNA prepared from the peripheral blood of the subject.
The subject of this invention is preferably a human, more preferably an Asian, Caucasian, African, African American, or Hispanic.
Other methods of dosing warfarin can be combined with the investigation of the VKORCI gene. For example, the sequence of the CYP2C9 gene can also be examined based on knowledge available in the art. For example, both CYP2C9*2 and CYP2C9*3 are associated with warfarin sensitivity.
An additional aspect of the present invention provides a method of determining the dose range of warfarin for a subject, comprising investigating the activity of the promoter of the VKORCI gene of the subject. A higher promoter activity is indicative of higher warfarin dose requirements.
Yet another aspect of the present invention provides a kit for determining the dose range of warfarin, comprising at least one component selected from the group consisting of:
(a) a means for detecting sequence A at the-1639 position of the VKORC1 gene; and
(b) a means for detecting sequence G at the -1639 position of the VK.ORC1 gene.
The kit can further comprise a means for detecting sequence C and T at the -1639 position of the VKORC1 gene, respectively. Thus, in certain embodiments, the kit may comprise a means for detecting each of the four possible bases at this position. In other embodiments, the kit may contain a means for detecting A, and a means for detecting G, C or T at this position, since the presence of an A at this position is the most indicative of warfarin sensitivity. The means is preferably an oligonucleotide. The kit may optionally comprise the reagents for oligonucleotide hybridization, PCR amplification, and/or instructions of use.
Another aspect of the present invention provides an oligonucleotide, or complement thereof, that hybridizes to a region of the VKORC1 gene promoter, wherein the region spans the -1639 position of the promoter and consists of at least 6 nucleotides. Preferably, the oligonucleotide specifically hybridizes with at least 6, 8, 10,12,14, 16, 18, 20, 22 or 24 nucleotides spanning the -1639 position of the VKORC1 gene. The oligonucleotide can hybridize to this region wherein the nucleotide at the -1639 position is A, G, C or T, preferably A or G In certain embodiments, the oligonucleotide may consist of about 15 nucleotides or less, 16-20 nucleotides, 20-25 nucleotides, 25-30 nucleotides, or 30-40 nucleotides. An array comprising the oligonucleotide of this invention is also provided.
The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.
DESCRIPTION OF DRAWINGS
Figure 1. Scatter plot of warfarin doses against the VKORC1 -1639 genotype. Warfarin doses in selected patients with warfarin sensitivity or resistance (see Table 1 for details) were plotted against different genotypes at the VK.ORC1 promoter -1639 position. *Individuals with CYP2C9 variants including CVp2C9*3, T299A (i.e., amino acid residue 299 changed from T to A) and P382L (i.e., amino acid residue 382 changed from P to L).
Figure 2. The relative measurements ofluciferase activity levels in HepG2 cells. pGL3 luciferase reporter containing either the A (pGL3-A) or G allele (pGL3-G) at the promoter -1639 position. The average of the data from 9 experiments is presented, and the error bars represents standard deviation. pGL3-basic was used as control without any promoter sequence inserted.
Figure 3. The genomic sequence of the VKORC1 gene (Genbank Accession No. AY587020). The transcription start site is at nucleotide number 5086 (bolded and boxed) in this figure, which is designated as +J of the gene in the traditional nomenclature. The A of the ATG translation initiation codon (bolded) is at nucleotide number 5312 in this figure, which is recommended by the Human Genome Variation Society to be designated as +1 in the new nomenclature system. The promoter polymorphism described in this invention is underlined and bolded (nucleotide number 3673 in this sequence), which is at -1413 in the traditional system and -1639 in the new, recommended system.
We discovered that a polymorphism in the promoter of the VKORC1 gene is associated with warfarin sensitivity. This polymorphism can explain both the inter-individual and inter-ethnic differences in warfarin dose requirements. Furthermore, the polymorphism is also associated with promoter activity. The VKORCl promoter having a G at the -1639 position (numbered with respect to the first nucleotide of the initiation codon) is 44% more active than the promoter having an A at the same position. Patients with the -1639A polymorphism are more sensitive to warfarin. Homozygous AA patients at the -1639 position had the lowest dose requirements,
heterozygous AG had intermediate dose requirements and the homozygous GG patients had the highest dosage. Thus, the promoter sequence or activity of the VKORC1 gene of a subject can be used to predict how much warfarin should be prescribed for the subject.
Prior to describing the invention in further detail, the terms used in this application are defined as follows unless otherwise indicated.
The term "warfarin" encompasses coumarin derivatives having an anticoagulant activity. A preferred embodiment, warfarin, is 4-hydroxy-3-(3-oxo-l-phenylbutyl)-2H-l-benzopyran-2-one (i.e., 3-a-pheneyl-p~acetylethyl-4-hydroxycoumarin). The current commercial product is a racemic mixture of the R-isomer and the S-isomer. The term "warfarin" encompasses the R-isomer, the S-isomer, any racemic mixture, and any salt thereof. Specifically included as warfarin are Coumadin, Marevan, Panwarfin, Prothromadin, Tintorane, Warfilone, Waran, Athrombin-K, warfarin-deanol, Adoisine, warfarin acid, Coumafene, Zoocoumarin, Phenprocoumon, dicumarol, brodifacoum, diphenadione, chlorophacinone, bromadiolone, and acenocoumarol.
An "oligonucleotide", as used herein, is a molecule comprising 2 to about 100 contiguous nucleotides linked via nucleotide bonds. An oligonucleotide may be at least about 10,20, 30,40, 50, or 60 nucleotides long. In addition, an oligonucleotide is preferably up to about 200, and more preferably up to about 150, 100, 75, 50, 40, 30, or 20 nucleotides long.
A hybridization "probe" is an oligonucleotide that binds in a base-specific manner ,to a complementary strand of nucleic acid. Such probes include peptide nucleic acids. Probes can be any length suitable for specific hybridization to the target nucleic acid sequence. The most appropriate length of the probe may vary depending upon the hybridization method in which it is being used; for example, particular lengths may be more appropriate for use in microfabricated arrays, while other lengths may be more suitable for use in classical hybridization methods. Such optimizations are known to the skilled artisan. Suitable probes and primers typically range from about 8 nucleotides to about 100 nucleotides in length. For example,
probes and primers can be about 8-20,10-30,15-40,50-80, and preferably 12-20 nucleotides in length. The nucleotide sequence can correspond to the coding sequence of the gene or to the complement of the coding sequence of the gene.
Methods and Compositions
Upon comparing the CYP2C9 and VKORC1 DNA sequences of Chinese patients with warfarin sensitivity or resistance (Example 1), we found that CYP2C9 DNA sequence variants were present in only 5.4-7.3% of the Han Chinese population. The variants were primarily CYP2C9*3. In addition, two missense mutations identified in this study, including a novel mutation (P382L) not previously reported, were rare and present only in warfarin-sensitive patients. The CYP2C9 variants also showed different prevalence in different ethnic populations. CYP2C9*l/*2 was present in 20% of the Caucasian population (17); however, it was completely absent in the Chinese population in this study. Therefore, mutations in CYP2C9 can account for only a small percentage of warfarin sensitivity in the Chinese population and cannot explain the inter-ethnical differences in warfarin dose requirements.
On the other hand, we found that changes in the VKORC1 gene can alter warfarin dosage requirements both inter-individually in the Chinese population and inter-ethnically between Chinese and Caucasians. Patients with the -1639 promoter polymorphism AA genotype had lower dose requirements while the AG/GG genotypes had higher dose requirements (Examples 1 and 2). Furthermore, homozygous AA are rare in the Caucasian population, while this genotype makes up the majority of the Chinese population (Example 3). The differences in the genotype frequencies between Caucasians and Chinese, and the correlation of AA with warfarin sensitivity, are in concordance with what has been observed clinically that the Chinese population requires a lower dose than the Caucasian population.
Accordingly, one aspect of the present invention provides a method of determining the dose range of warfarin for a subject, comprising investigating the sequence of the promoter of the VKORC1 gene of the subject. The promoter sequence preferably contains less than 10%, 8%, 6%, 4%, 3%, 2%, or 1% variation within 3 kb from the translation initiation site compared to SEQ ID NO:l. More preferably, the promoter contains less than 20,15, 12, 10, 8, 6, 4, 3 or 2 single base
variations in this 3 kb region. Such a sequence variation, coupled with a change in promoter activity, is indicative of the dose range of warfarin that should be prescribed.
In particular, the sequence at the -1639 position of the VKORC1 gene is investigated. This SNP alone can be used to predict warfarin sensitivity without having to consult any other genotype. Thus, homozygous AA at this position is indicative of warfarin sensitivity, heterozygous AG indicates intermediate sensitivity, and subjects with homozygous GG are relatively resistant. The actual dosage of warfarin that should be given to subjects who are sensitive, intermediately sensitive, or relatively resistant would vary with the warfarin formulation as well as the indication and symptoms of the subject, and can be determined by the physician prescribing the warfarin. For example, our study (Example 1) shows that in a selected patient group with warfarin sensitivity or resistance, the patients with the lowest dose requirements (mean 1.19 mg/day, range 0.71-1.50 mg/day) had the AA genotype, those with the intermediate dose requirements (mean 8.04 mg/day, range 6.07-10 mg/day) had heterozygous AQ and the highest dose requirements (mean 9.11 mg/day, range 8.57-10 mg/day) were associated with the homozygous GG genotype. In randomly selected patients (Example 2), the AA genotype is associated with a lower maintenance dose (2.61 +/-1.10 my/day) than AG and GG (3.81 +/-1.24 mg/day). These ranges can serve as the starting points in dosing warfarin.
The genomic sequence of the VKORC1 gene is available as Genbank Accession No. AY587020 (SEQ ID NO.l; Figure 3). The sequence of VKORC1 isoform 1 mRNA is available as Accession Number NMJD24006.4. In both of these sequences, the start site of transcription is designated as +1, thus the promoter polymorphism indicative of warfarin sensitivity described herein would be located at the -1413 position. However, according to the recent recommendations by the Human Genome Variation Society (HGVS) for the description of sequence variations (http://www.genomic.unimelb.edu.au/mdi/ mutnomen/), the promoter SNP is recommended to be described in relation to the A of the ATG translation initiation codon. Under this nomenclature, the A of the ATG translation initiation codon (Met) of NM_024006.4 or AY587020 would be position +1, the promoter SNP described herein would be at position -1639, and the G>A polymorphism at this position would be referred to as "NM_024G06.4x.-1639G>A". It should be clarified that the -1639
G>A polymorphism (or more precisely "NMJ)24006.4:c.-1639G>A") of this disclosure is the same as the -1413 G>A polymorphism according to traditional promoter sequence numbering.
In addition to the specific polymorphism (e.g., AA, AG or GG at the -1639 position), genetic markers that are linked to each of the specific SNPs can be used to predict the corresponding warfarin sensitivity as well. This is because genetic markers near the SNP of interest tend to co-segregate, or show a linkage disequilibrium, with the SNP of interest. Consequently, the presence of these markers (equivalent genetic markers) is indicative of the presence of the SNP of interest, which, in turn, is indicative of the level of warfarin sensitivity.
The VKORC1 -1639 A > G promoter polymorphism is in linkage disequilibrium with the VKORC1 1173 OT intronic polymorphism recently reported by D'Andrea et al. (27) and may explain their results that Italian patients with the 1173 TT genotype had the lower average daily dose than the CT or CC genotype. Our study also shows that the 3730 (i.e., rs7294) G> A polymorphism, which is located in the 3' untranslated region, is in linkage disequilibrium with -1639 A>G and 1173 C>T in the Chinese population. Specifically, the 3730G allele is associated with the -1639A allele and the 1173T allele. Other equivalent genetic markers of the -1639 SNP include rs9934438 (intron 1), rs8050894 (intron 2) and rs2359612 (intron 2), Thus, -1639A is linked with T at rs9934438, C at rs8050894, T at rs2359612 and G at rs7294, while -1639G is linked with C at rs9934438, G at rs8050894, C at rs2359612 and A at rs7294.
The equivalent genetic marker can be any marker, including microsatellites and single nucleotide polymorphism (SNP) markers. Preferably, the useful genetic markers are about 200 kb from the VKORC1 -1639 position or less. More preferably, the markers are about 100 kb, 80 kb, 60 kb, 40kb, 20 kb, 15 kb, 10 kb, or 5 kb from tbeVKORCJ -1639 position or Jess.
One aspect of the present invention provides oligonucleotides that are capable of hybridizing to the SNPs of this invention. The oligonucleotide will be useful, for example, as a hybridization probe or primer for the detection of the promoter sequence of the VKORC1 gene. The oligonucleotide preferably comprises the
sequence TGGCCGGGTGC (3668 to 3678 of SEQ ID NO:l), or the complement thereof. For the purpose of hybridization, it is preferable that the sequence corresponding the -1639 position is near the center of the oligonucleotide. Preferably, there are at least 4 nucleotides on each side of the sequence corresponding to -1639. The -1639 corresponding position is more preferably flanked by at least 5, 6, 7, 8 or 9 nucleotides on each side.
. Hybridizations are usually performed under stringent conditions, for instance, at a salt concentration of no more than 1 M and a temperature of at least 25°C. For example, conditions of 5xSSPE (750 mM NaCl, mM NaPhosphate, mM EDT A, pH 7.4) and a temperature of 25-30°C, or equivalent conditions thereof, are suitable for single nucleotide-specific probe hybridizations. More preferably, a low stringent wash after hybridization is conducted, which includes, for example, 42°C, 5xSSC, and 0.1 % SDS; or 50°C, 2xSSC, and 0.1 % SDS. High-stringent wash conditions are most preferable and include, for example, 65°C, O.lxSSC, and 0.1% SDS. Equivalent conditions can be determined by varying one or more of the parameters, as known in the art, while maintaining a similar degree of identity or similarity between the target nucleotide sequence and the primer or probe used.
The -1639 promoter SNP is located in an E-Box (the consensus sequence of E-boxes is CANNTG), and within a short distance (200 bp), there are three additional E-boxes. E-boxes have been shown to be important elements for mediating cell/tissue type specific transcription, such as in muscle, neurons, liver and pancreas (28, 29). Changing the second base from A to G as observed at the -1639 site would abolish the E-box consensus and alter the promoter activity. This was clearly demonstrated by the promoter assay that in HepG2 cells the promoter activity was increased by 44% when the consensus sequences was abolished (Figure 2). Without wishing to be limited by theory, this suggests that the E-box may function as a repressor binding site in HepG2. Since HepG2 was derived from a hepatoma, it is likely that the -1639 E-box represses transcription in the liver.
The fact that people with the -1639 GG genotype require a higher warfarin dose can be explained as follows. The VKORC1 gene codes for subunit 1 of vitamin K epoxide reductase complex, which is responsible for regenerating the reduced form of vitamin K. The reduced form of vitamin K is required by gamma-carboxylase, and
gamma-carboxylation of vitamin K-dependent clotting factors (factor II, VII, IX, and X) is essential for blood clotting. When VKORCI promoter activity is increased, an elevated level of VKORCI mRNA can lead to higher VKOR activity (25) and thus enhance the efficiency of regeneration of reduced vitamin K. Thus, gamma-carboxylation of the vitamin K dependent clotting factors is enhanced due to the higher level of reduced vitamin K. Warfarin acts by blocking clotting factor synthesis, and having more active clotting factors would require more warfarin for its anti-coagulation effect. Since liver is the primary organ for the synthesis of vitamin K dependent clotting factors and VKORCI's expression is highest in the liver, a 44% change in the level of VKORCI in the liver is likely to have a significant impact on the blood clotting process. Thus, warfarin dose requirements are associated with VKORCI gene polymorphism and its promoter activity,
We contemplate that any sequence at the -1639 position of the VKORCI promoter, other than an A, will destroy the E-box and increase promoter activity. An increase in promoter activity, in turn, increases warfarin dose requirements. Thus, the promoter sequence, particularly the sequence at the -1639 position, is indicative of warfarin dosages. Furthermore, other embodiments of the present invention provide methods of dosing warfarin, or determining warfarin sensitivity, by detecting the promoter activity of the VKORCI gene. Similarly, the level of the gene product of the VKORCI gene (either mRNA or protein) or VKOR activity can also reflect warfarin dose requirements. A VKORCI promoter activity, mRNA level, protein level or VKOR activity that is at least 10%, 15%, 20%, 25%, 30%, 35% or 40% more than that of a subject having the AA genotype is indicative of the requirement for a higher dose of warfarin than the subject with the AA genotype.
Methods of determining promoter activities or levels of mRNA or proteins are well known in the art. In certain embodiments, PCR can be employed to detect mRNA level. In other embodiments, specific antibodies are used to measure the VKORCI protein, promoter activities can be examined, for example, by isolating the promoter sequence from the subject of interest using a peripheral blood sample, linking the promoter sequence to a reporter gene, expressing the reporter gene, and determining the amount of the reporter produced. Methods of measuring VKOR activities are also known in the art.
An additional aspect of the present invention provides a method of determining if a given mutation of the VKORC1 gene will impact warfarin dosing. In this method, the promoter activity, mRNA level, protein level, or VKOR activity resulted from the mutation is determined and compared to that of the corresponding wild-type VKORC1 gene. If the promoter activity, mRNA level, protein level or VKOR activity is increased or decreased by at least 10%, 15%, 20%, 25%, 30%, 35% or 40% compared to the wild-type, the physician should consider increasing or decreasing warfarin dosing.
Yet another aspect of the present invention provides a kit for determining the dose range of warfarin, comprising at least one component selected from the group consisting of:
(a) a means for detecting sequence A at the -1639 position of the VKORC1 gene; and
(b) a means for detecting sequence G at the -1639 position of the VKORC1 gene.
The kit can further comprise a means for detecting sequence C and T at the -1639 position of the VKORC1 gene, respectively. Thus, in certain embodiments, the kit may comprise a means for detecting each of the four possible bases at this position. In other embodiments, the kit may contain a means for detecting A, and a means for detecting Q C or T at this position, since the presence of an A at this position is the most indicative of warfarin sensitivity. The means is preferably an oligonucleotide. The kit may optionally comprise the reagents for oligonucleotide hybridization, PCR amplification, and/or instructions of use.
Another aspect of the present invention provides an oligonucleotide, or complement thereof, that hybridizes to a region of the VKORC1 gene promoter, wherein the region spans the -1639 position of the promoter and consists of at least 6 nucleotides. Preferably, the oligonucleotide specifically hybridizes with at least 6, 8, 10,12,14,16,18,20,22 or 24 nucleotides spanning the -1639 position of the VKORC1 gene. The oligonucleotide can hybridize to this region wherein the nucleotide at the -1639 position is A, Q C or T, preferably A or G In certain . embodiments, the oligonucleotide may consist of about 15 nucleotides or less, 16-20 nucleotides, 20-25 nucleotides, 25-30 nucleotides, or 30-40 nucleotides. An array comprising the oligonucleotide of this invention is also provided.
The following examples are offered to illustrate this invention and are not to be construed in any way as limiting the scope of the present invention. While this invention is particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.
In the examples below, the following abbreviations have the following
meanings. Abbreviations not defined have their generally accepted meanings.
°C = degree Celsius
hr = hour
min = minute
sec or s = second
uM = micromolar
mM = millimolar
M = molar
ml = milliliter
μl = microliter
mg = milligram
μg = microgram
mol = mole
pmol = picomole
ASO = allele specific oligonucleotide
CYP2C9 = cytochrome P450, subfamily l\C;polypeptide 9
IND = international normalized ratio
LD = linkage disequilibrium
NTP = nucleoside triphosphate
PBS = phosphate buffered saline
PCR = polymerase chain reaction
SNP = single nucleotide polymorphism
VKORC1 = vitamin K epoxide reductase complex, subunit 1
Materials and Methods
We recruited 16 patients who received warfarin either at low or high dose from cardiovascular clinics of four major medical centers in Taiwan (National Taiwan University Hospital, Kaohsiung Medical University Hospital, Taipei General Veteran Hospital, and Shin-Kong Wu Ho-Su Memorial Hospital). The mean maintenance
dose of warfarin in Chinese patients is 3.3 tng/day (8,9). Therefore, we considered patients who received maintenance dose 6 mg per day as warfarin resistant (Table 1, 5 patients). The definition of the warfarin-resistant patients was supported by our own data that none of the randomly selected patients (Table 2) had warfarin dose greater than 6 mg/day. This is in contrast to Caucasian patients, who had an average maintenance dose between 5.1 and 5.5 mg/day (20, 27).
The average daily dose of warfarin was calculated from a one-week-period, and the latest international normalized ratio (INR) of each patient was recorded. The randomly recruited 104 patients who received warfarin, regardless of the dose, had a target INR of 1.4 to 3 from the same 4 hospitals (Table 2). The indications of warfarin were: valve replacement (90 patients), deep vein thrombosis (5 patients), atrial fibrillation (5 patients), and stroke (4 patients). Clinical information (including age, sex, weight, and average daily maintenance dose) was obtained from every participant. At the time of blood draw, every patient had had a constant maintenance dose for at /east three weeks. Patients with liver, kidney, gastro-intestinal cancer, or abnormal bleeding problems before warfarin therapy were excluded.
In addition, DNA samples from 92 unrelated Caucasians (Cat. No, HD100CAU, National Institute of General Medical Sciences (NIGMS) Human Genetic Cell Repository, Camden, NJ, USA) were used as Caucasian controls. DNA samples from 95 healthy subjects randomly selected from a biobank under a nationwide population study, in which 3312 Han Chinese descendants were recruited based on the geographic distribution across Taiwan, were used as Chinese controls. The Chinese controls and all participating patients receiving warfarin therapy were unrelated Han Chinese residing in Taiwan. The Han Chinese forms the largest ethnic group in Taiwan, making up roughly 98 percent of the population. None of the participants were aboriginal Taiwanese, which account for the remaining 2% of the Taiwan's population.
The study was approved by the institutional review board, and informed consent was obtained from all of the participants.
DNA sequencing and single nucleotide polymorphism (SNP) genotyping
Genomic DNA was isolated using the PUREGENE™ DNA purification system (Gentra systems, Minnesota, USA). CYP2C9 and VKORC1DNA sequence variants were first determined by direct sequencing (Applied Biosystems 3730 DNA analyzer, Applied Biosystems, Foster City, CA, USA) in 16 Han Chinese patients having warfarin sensitivity ( 6.0 mg/day, 5 patients). Primers were specifically designed for the intron-exon junctions, exons and 2 kbps upstream of the transcription start site for both CYP2C9 and VKORC1 using the Primer3 PCR primer program (http://fokker.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). The primers used to detect variants in the VKORC1 promoter were: 5'- CAGAAGGGTAGGTGCAACAGTAA (SEQ ID NO:2; sense strand located 1.5 kb upstream of the transcription start site) and 5'-CACTGCAACTTGTTTCTCTTTCC (SEQ ID NO:3; anti-sense strand located 0.9 kb upstream of the transcription start site). The polymerase chain reactions (PCR) were performed in a final volume of 25 μl, containing 0.4 uM of each primer, 10 mM Tris-HC1 (pH8.3), 50 mM KCI, 1.5 mM MgCl2, 0.2 mM dNTPs and 1 unit HotStart Taq™ (Qiagen Inc, Valencia, CA, USA). Amplification conditions consisted of an initial denaturation of 12 min at 96°C, followed by 34 PCR cycles in 30 sec at 96°C, 30 sec at 60°C, 40 sec at 72°C.
MALDI-TOF mass spectrometry (SEQUENOM MassARRAY system, Sequenom, San Diego, CA, USA) was then used to screen for the identified variants in 104 randomly selected Chinese patients receiving warfarin, 95 normal Chinese controls and 92 normal Caucasian controls. Briefly, primers and probes were designed using the SpectroDESIGNER software (Sequenom). Multiplex PCR was performed, and unincorporated dNTPs were dephosphorylated using shrimp alkaline phosphatase (Hoffman-LaRoche, Basel, Switzerland), followed by primer extension. The purified primer extension reactions were spotted onto a 384-element silicon chip (SpectroCHIP, Sequenom), analyzed in the Bruker Biflex III MALDI-TOF SpectroREADER mass spectrometer (Sequenom), and the resulting spectrum was processed with SpectroTYPER (Sequenom).
Luciferase reporter, assay
To assay for the VKORC1 promoter activity, the VKORC1 promoter encompassing the -1639 polymorphism (from -1798 to -35) from patients with -1639 AA and -1639 GG genotypes was first cloned into the pGEM-T Easy vector (Promega, Madison, WI, USA) with the forward primer: 5'-
ccgctcgagtagatgtgagaaacagcatctgg (SEQ ID NO:4; containing an Xhol restriction site) and the reverse primer: 5'-cccaagcttaaaccagccacggagcag (SEQ ID NO:5; containing a Hindlll restriction site). The fragment containing the VK.ORC1 promoter was released from the pGEM-T Easy vector by digesting the vector with Xhol and Hindlll restriction enzymes and sub-cloned into the multiple cloning sites (Xhol and Hindlll) of pGL3-basic vector (Promega). The pGL-3 vector contains the cDNA encoded for firefly luciferase, which when fused with a promoter, can be used to analyze the inserted promoter activity upon transfection into mammalian cells. The vector containing the -1639 G/G genotype was designated pGL3-G and the vector containing the -1639 A/A genotype was designated pGL3-A. VKORC1 promoter sequences in both vectors were confirmed by direct sequencing analysis.
Cell culture and dual, luciferase reporter assay
HepG2 cells were grown in Dulbecco's modified Eagle medium (DMEM) and 10% fetal calf serum supplemented with 100 units/mL Penicillin, 100 μg/mL Streptomycin and 2 mM L-Glutamine. Twenty-four hours prior to transfection, 1.5 x 105 cells were seeded in each well of a 12-well plate. On the day of transfection, each well was co-transfected with 1.5 |ig of the pGL3 vector and 50 ng of the pRL-TK vector (Promega) using lipofectamine 2000 (Invitrogen Corporation, Carlsbad, CA, USA). 'The pRL-TK vector encoded the Renilla luciferase transcribed by a HSV-TK promoter, which was used as an internal control to normalize firefly luciferase expression. Forty-eight hours after transfection, the cells were lysed in passive lysis buffer (Promega). The cell lysate was added to the luciferase substrate (dual luciferase reporter system, Promega) and the Firefly and Renilla luciferase activities were measured with a luminometer (SIRIUS, Pforzheim, Germany).
. The genotype frequencies of each SNP were counted. The Chi-square test was used to compare genotype frequencies of each SNP for the three sample groups. T-test and Wilcoxon-Mann-Whitney test were performed for multiple comparisons of mean dose levels among the different genotype groups. Inter-marker linkage disequilibrium was assessed by two measures, D' and r2, calculated using Graphical Overview of Linkage Disequilibrium (GOLD, http://www.sph.umich.edu/csg/abecasis/GOLD/).
EXAMPLE 1 CYP2C9 and VKORC2 DNA sequence variants In selected Chinese patients with
warfarin sensitivity or resistance
The mean maintenance dose of warfarin in Chinese is 3.3 mg/day (8,9). Therefore, we considered patients who received maintenance dose 6 mg per day as warfarin resistant (Table 1, 5 patients, see Materials and Methods for further details). Sequencing of the coding regions, exon-intron junctions, and the promoter region of the CYP2C9 gene revealed three sequence variants in 4 of the 11 warfarin sensitive patients. The variants were: 1075 A > C (I359L known as CYP2C9*3),895A>G(T299A),and 1145 C>T(P382L). CYP2C9*3 was detected in 3 patients (subjects 1, 3, and 5, Table I). Subject 5, in addition to CYP2C9*3, also tiad the 895 A > G (T299A) change as previously described (7). A novel exonic mutation, 1145 OT (P382L), was detected in the fourth patient (subject 6). As shown -in Table 1, CYP2C9 gene variants were not present in all warfarin sensitive patients and were completely absent in all warfarin resistant patients.
We also sequenced the promoter, coding regions, and the exon-intron junctions oftheVKORCl gene. One variant (3730 G> A) which was located in 3'un-translated region (UTR) of VKORC1 was detected. In addition, a promoter polymorphism, -1639 G> A (or -1413 using transcription start site as +1) was detected in the upstream region of VKORC1. This polymorphism showed an association with warfarin sensitivity in that all warfarin sensitive patients were
homozygous AA at position -1639. The warfarin-resistant patients, on the other hand, were either heterozygous AG or homozygous GG (Table 1). When warfarin doses were plotted against the -1639 genotypes, it was demonstrated that patients with the AA genotype had the lowest dose requirements (mean 1.19 mg/day, range 0.71 -1.50 mg/day), heterozygous AG had intermediate dose requirements (mean 8.04 mg/day, range 6.07-10 mg/day), and the homozygous GG genotype had the highest dose requirements (mean 9.II mg/day, range8.57-20mg/day) (Figure I).
In addition to the -1639 G> A, an intron 1 polymorphism 1173 OT, which has been described by D'Andrea et al. (27), was also identified in our patients. These two polymorphisms appeared to be in strong linkage disequilibrium (LD) (Table 1). Warfarin-sensitive patients with the -1639 AA genotype were found to be associated with the 1173 homozygous TT except for one patient (subject 6). In warfarin-resistant patients, patients with the -1639 heterozygous AG genotype were found to be associated with 1173 heterozygous CT, and homozygous -1639 GG was found to be associated with 1173 homozygous TT (Table 1).
EXAMPLE 2 VKORC1 -1639 G>A polymorphism in random Chinese patients receiving
1 To farther investigate whether the -1639 G> A polymorphism was associated with the inter-individual differences in warfarin dosage, we genotyped 104 patients receiving warfarin regardless of the dose, using MALDI-TOF mass spectrometry. The AA and AG/GG groups did not differ with respect to age, sex, and INR (Table 2). Only two patients were found to be homozygous for GG, and they were grouped together with AG for statistic analysis. We analyzed the data regardless of the presence of other confounding variables, such as diet or other medications. As shown in Table 2, the AA group had significantly lower dose requirements (2.61 mg/day) than the AG/GG group (3.81 mg/day). The differences were significant by either T test (p
Table 2. Mean doses and other clinical characteristics of randomly selected patients on warfarin stratified according to the genotypes.
aP value of comparison between AA and AG+GG groups, P-value EXAMPLE 3
Genotype frequencies of VKORC1 -1639 G > A polymorphism and CYP2C9
variants in Chinese and Caucasians
The Chinese population has been known to require a much lower warfarin maintenance dose than the Caucasian population. To test whether differences in the VKORC1 -1639 genotype frequencies could account for the inter-ethnic differences in warfarin dosages, 95 normal Han Chinese subjects and 92, normal Caucasian subjects were genotyped. In the Caucasian population, homozygous AA had the lowest frequency, while the AG and GG genotypes made up the inajority of the population (14.2%, 46.7% and 39.1% respectively, Table 3). In the Chinese population, on the contrary, homozygous AA made up the majority of the population (82.1 %), with the rest of the population being heterozygous AG (17.9%). N0 homozygous GG was detected in this randomly selected population. This ratio was also similar in the 104 warfarin patients in which 79.8% were found to be homozygous AA, 18.3% were heterozygous AQ and the remaining 1.8% were homozygous GG The differences in genotype frequencies between the Caucasian group and the two Chinese groups were significant, with the p values less than 0.0001. These differences between the two ethic groups (Caucasians and Chinese) and the correlation of AA with warfarin sensitivity are in concordance with the clinics] observation that the Chinese population requires a lower dose than the Caucasian population.
Table 3. Genotype frequencies of VKORC1 promoter polymorphism (-1639 G>A) and CYP2C9 variants in Chinese and Caucasians.
P value P value patients.
P value = 0.817 compared between Chinese and random selected warfarin patients.
aCYP2C9*l is wild type of CYP2C9. CYP2C9*2 and CYP2C9*3 are variants with
cystine substitutes for arginine at residue 144 and leucine substitutes for isoleucine at
residue 359, respectively. Frequencies in Caucasian were obtained from published
bCYP2C9*3 frequency was derived from genotyping 74 warfarin patients.
In addition to -1639 G> A, we screened for three intronic polymorphisms (rs9934438, intron 1 1173 C>T; rs8050894, intron 2 g.509+124C; and rs2359612, intron 2 g.509+837C) and one 3' UTR polymorphism (rs7294, 3730 G> A) in the Chinese population. All four polymorphisms were in linkage disequilibrium with the -1639 promoter polymorphism (Inter-markcr D' and r2 values = 1.0).
CYP2C9 variants were also genotyped in the Chinese groups. The frequency of CYP2C9* 1 /*3 was 7.3% in Chinese normal population and 5.4% in the randomly selected Chinese patients receiving warfarin. CYP2C9*2 variant was not detected in the Chinese patients or controls. Compared to the,published data on the CYP2C9
variant frequency in Caucasians, the Caucasian population had a much higher frequency of CYP2C9 variants than Chinese (-30% versus 7%), yet Caucasians are more resistant to warfarin. Other missense mutations detected in the warfarin sensitive patients, 895 A>G (T299A) and 1145 C>T (P382L) (Table 1) were not found in any of the randomly selected patients and controls, suggesting that these were rare mutations.
EXAMPLE 4 VKORC1 promoter activity
The differences in warfarin sensitivity between the AA and the GG genotype patients could be explained by changes in the VK.ORC1 promoter activity. The -1639 promoter SNP was located in the second nucleotide of an E-Box (CANNTG), and therefore, this polymorphism would alter the E-box consensus sequence and could lead to changes in the VK.ORC1 promoter activity. To test this hypothesis, the VKORC1 promoter encompassing the -1639 position was PCR-amplified from patients with the -1639 AA or GG genotype and cloned into the pGL-3 vector. HepG2 cell (a human hepatoma cell line) was chosen for the promoter assay because VKORC1 is expressed at the highest level in the liver. A total of 9 experiments were performed, and all demonstrated consistent results (shown in Figure 2). The -1639 G VKORC1 promoter exhibited higher luciferase activity (approximately 44% higher) compared to the -1639 A promoter. The pGL-3 basic vector control did not have any promoter inserted in the multiple cloning site and had a negligible amount of luciferase activity. Therefore, the sequence at the -1639 position is important for promoter activity, and higher promoter activity (e.g., -1639G) is associated with higher warfarin dose requirements.
EXAMPLE 5 Combination of the VKGRC1 -1639 SNP and CYP2C9 variants in warfarin
Although the VKORC1 -1639 SNP alone can be used to predict warfarin sensitivity, this SNP can optionally be combined with other genetic marker(s). For example, the sequences of both the VKORC.1 gene and the CYP2C9 gene can be examined in warfarin dosing. The following table illustrates the suggested Coumadin doses for each haplotype when these two genes are both considered:
A number of embodiments of the invention have been described, Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention.
We Claim :
1. A method of determining the dose range of a warfarin for a subject, comprising investigating the sequence of the promoter of the VKORC1 gene of the subject.
2. The method of claim I wherein the sequence at the -1639 position of the VKORC1 gene is investigated.
3. The method of claim 1 or 2 wherein homozygous AA at the -1639 position of the VKORC1 gene is indicative of warfarin sensitivity.
4. The method of any one of the preceding claims wherein the sequence is investigated by assaying for an equivalent genetic marker of the -1639A or -1639G/C/T allele, wherein the presence of the equivalent genetic marker is indicative of the presence of the corresponding allele.
5. The method of claim 4 wherein the equivalent genetic marker is an SNP selected from the group consisting of 3730G of the VKORC1 gene, rs9934438, rs8050894, rs2359612 and rs7294, each of which is indicative of warfarin sensitivity.
6. The method of any one of claims 1-3 wherein the sequence is investigated by using an oligonucleotide that specifically hybridizes with the promoter of the VKORCl gene.
7. The method of claim 6 wherein the oligonucleotide specifically hybridizes with at least 6 nucleotides spanning the -1639 position of the VK.ORC1 gene.
8. The method of any one of the preceding claims wherein the sequence is investigated by using DNA prepared from the peripheral blood of the subject.
9. The method of any one of the preceding claims wherein the subject is an Asian.
10. The method of any one of claims 1-8 wherein the subject is a Caucasian.
11. The method of any one of claims 1 -8 wherein the subject is an African,
African American, or Hispanic.
12. The method of any one of the preceding claims further comprising
examining the sequence of the CYP2C9 gene.
13. A method of determining the dose range of a warfarin for a subject, comprising investigating the activity of the promoter of the VKORC1 gene of the subject.
14. The method of claim 13 wherein a lower dose should be prescribed if the promoter activity is at least about 20% lower than a promoter comprising residues 3514 to 5277 of SEQ ID NO:l.
15. A kit for determining the dose range of a warfarin, comprising at least one component selected from the group consisting of:
(a) a means for detecting sequence A at the -1639 position of the VKORC1 gene; and
(b) a means for detecting sequence G at the -1639 position of the VKORC1 gene.
16. The kit of claim 15 wherein the means of (a) and the means of (b) are oligonucleotides.
17. An oligonucleotide, or complement thereof, that hybridizes to a region of the VKORC1 gene promoter, wherein the region spans the -1639 position of the promoter and consists of at least 6 nucleotides.
18. The oligonucleotide of claim 17 wherein the nucleotide at the -1639 position of the promoter is an A or a G
19. The oligonucleotide of claim 17 comprising the sequence
TGGCCGGGTGC (3668 to 3678 of SEQ ID NO:l) or the complement thereof.
20. The oligonucleotide of any one of claims 17-19 consisting of about 15 nucleotides or less.
21. The oligonucleotide of any one of claims 17-19 consisting of 16-20 nucleotides.
22. The oligonucleotide of any one of claims 17-19 consisting of 20-25 nucleotides.
23. The oligonucleotide of any one of claims 17-19 consisting of 25-30 nucleotides.
24. The oligonucleotide of any one of claims 17-19 consisting of 30-40 nucleotides.
25. An array of oligonucleotides comprising the oligonucleotide of any one of claims 17-24.
26. A genetic variants predicting warfarin sensitivity as claimed
substantially as herein described with forgoing description and drawings.
Dated this 10th Day of July 2007.
|Indian Patent Application Number||1052/MUMNP/2007|
|PG Journal Number||04/2011|
|Date of Filing||13-Jul-2007|
|Name of Patentee||ACADEMIA SINICA|
|Applicant Address||128 SEC. 2, ACADEMIA SINICA ROAD, NAN-KANG, TAIPEI|
|PCT International Classification Number||C12Q1/68|
|PCT International Application Number||PCT/US2005/046869|
|PCT International Filing date||2005-12-21|